On November 17, Kodiak Sciences Inc. fell 4.1% in Regular Trading, trading at $97.21 per share, with turnover of $14.46 million.
The move appears tied to continued market digestion of the company’s latest quarterly results, with investor focus remaining on a wider loss, elevated cash burn concerns, and higher research spending.
For the September quarter, Kodiak Sciences Inc. reported EPS of $(1.05), missing the $(1.01) consensus estimate. Net loss widened 8% year over year to $66.22 million, while research and development expense rose 16% to $58.30 million, driven mainly by increased clinical and manufacturing activity. While management said a multi-indication regulatory submission for Zenkuda remains planned for the fourth quarter, the near-term trading focus has stayed on profitability and expense pressure rather than pipeline progress.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments